Melanocortin Receptor Agonist (Corticotrophin) in Treatment of Refractory Diabetic Nephropathy | ||||
| Benha Journal of Applied Sciences | ||||
| Article 15, Volume 5, Issue 4 part (1), July 2020, Page 89-96 PDF (462.23 K) | ||||
| Document Type: Original Research Papers | ||||
| DOI: 10.21608/bjas.2020.136249 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| S.S. El-sayed; A.E. Mansour; A.T. Mahmoud; H.G. Abdelsalam; S.B. Hannalla; E.L. El-Shahawy | ||||
| Internal Medicine Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
| Abstract | ||||
| The aims of this study are to To assess the response and efficacy of melanocortin receptor agonist (ACTH) as a treatment for patients with refractory diabetic nephropathy . This study was performed on 50 diabetic patients who attended internal medicine department at banha university hospital. Patients with diabetic nephropathy presented with proteinuria more than 1gm/24hour urine collection and who are not responding to anti proteinuric measures for at least one month of treatment treated with synthetic ACTH allowing a 6 months follow-up. Outcome. The primary endpoint was the percentage of patients achieving a complete remission (<300mg/24 hours) within 6months. Exploratory endpoints included the percentage of partial (50% reduction) remissions, changes in Cr, eGFR. Results. After 6months of ACTH therapy, 29 patients (58%) had achieved a complete remission and nine patients had achieved partial remission (18%).Conclusion. ACTH gel stabilizes renal function and reduces urinary protein. | ||||
|
Statistics Article View: 119 PDF Download: 273 |
||||
